🏆 We’re excited to announce the finalists of the first HCP Impact Award, sponsored by Impiricus! Congratulations to our finalists: Razorfish Health & GSK CMI Media Group Level Ex Publicis Health Media Moon Rabbit & Tarsus Pharmaceuticals, Inc. Winners will be announced on Sept. 11th at the award gala: https://lnkd.in/e-nmEs_v #Sponsored #FiercePharma #FierceBiotech #FierceLifeSciences #Marketing #FiercePharmaMarketingAwards #WeAreFierce
Fierce Pharma
Internet News
New York, New York 91,829 followers
Pharma’s go-to destination for news & trends shaping approved drugs.
About us
Fierce Pharma is the go-to destination for the news and trends shaping the industry. Our focus daily is on news about approved drugs and every aspect of pharma’s operations as well as the people who move pharma forward. Our coverage also feeds longer-form content, podcasts and events. In staying on top of the news, our journalists have developed a loyal audience. Critically, we explain the news—often complicated technology or business maneuvers—and put it in context that brings it home for our readers and listeners in their work lives. Delivering news, revealing insights straight to your inboxes: https://fiercepharma.questexinfo.com/loading.do?omedasite=Pharma_full. Our family of publications includes Fierce Pharma, Fierce Pharma PM Tracker, Fierce Pharma Marketing, Fierce Manufacturing, Fierce Drug Delivery and Fierce Life Sciences Weekly Digest. Follow our podcast ‘The Top Line’ on Apple Podcasts, Spotify, Amazon, iHeart or wherever you get your podcasts. We dig into high-impact trends and recount the week’s biggest headlines. For Biotech news you can’t miss: https://www.linkedin.com/showcase/fierce-biotech For Healthcare news you can’t miss: https://www.linkedin.com/showcase/fierce-healthcare
- Industry
- Internet News
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Type
- Privately Held
- Founded
- 2006
Locations
-
Primary
685 3rd Ave
21st Floor
New York, New York 10017, US
Employees at Fierce Pharma
Updates
-
While manufacturing and supply hitches have troubled the rollout of Sanofi’s key RSV drug, the near-term expected approval of a pair of new filling lines is giving the French pharma assurance that its AstraZeneca-partnered antibody Beyfortus can breach the billion-dollar threshold before the year is out.
-
Just three months after scoring an accelerated FDA approval for Ojemda, Day One Biopharmaceuticals is teaming up with another fellow oncology specialist to grow the medicine's global reach.
With $111M upfront investment, Ipsen secures ex-US rights to Day One's pediatric cancer med
fiercepharma.com
-
A new 42-acre campus in New Jersey gives BeiGene CEO John Oyler hope that the company can strike new partnerships in biologics.
BeiGene CEO eyes biologics deals for new US innovation center in New Jersey
fiercepharma.com
-
Interim results from a phase 3 trial of AstraZeneca’s Imfinzi as a treatment before and after surgery in resectable non-small cell lung cancer were head-scratching as they failed to answer two key questions.
Ahead of adcomm, FDA pokes holes in AZ's perioperative lung cancer filing for Imfinzi
fiercepharma.com
-
After Hikma initiated a recall of one batch of acetaminophen injection earlier this month, the company is extending the nationwide recall to the consumer level.
Hikma extends recall of pain drug due to 'potential presence' of sedative, reports adverse event
fiercepharma.com
-
In HIV treatment, Gilead Sciences’ popular Biktarvy serves as a benchmark for newer drugs to overcome. In a new head-to-head study, GSK’s two-drug regimen Dovato showed comparable antiviral efficacy to the Gilead triplet.
GSK's Dovato matches Gilead's HIV juggernaut Biktarvy with less weight gain in Spanish trial
fiercepharma.com
-
After changing hands several times throughout the 2010s, Canadian specialty CDMO BIOVECTRA has agreed to fly the Agilent Technologies flag.
Agilent Technologies lays out $925M to acquire Canadian specialty CDMO Biovectra
fiercepharma.com
-
While the international IT outage caused by cybersecurity specialist CrowdStrike—and subsequently Microsoft—has grounded airlines and forced cancelations at hospitals, the experience from the meltdown appeared different at large pharma companies.
Pharma companies report various levels of exposure to IT outage caused by CrowdStrike, Microsoft
fiercepharma.com
-
As with GSK before it, Daewoong Bio’s manufacturing misstep has resulted in a ban for the Korean company from China’s bulk-buy drug procurement program.
Korea's Daewoong Bio banned from China drug procurement program after turning down inspection
fiercepharma.com